Browsing by Author "Samy, Kannan P."

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Bilateral Renal Auto-Transplantation for Retroperitoneal Sarcomas: Is It Underutilized?
    (MDPI, 2023-08-14) Robinson, Tyler P.; Milgrom, Daniel P.; Nagaraju, Santosh; Goggins, William C.; Samy, Kannan P.; Koniaris, Leonidas G.; Surgery, School of Medicine
    Sarcomas are a rare tumor of mesenchymal origin. The liposarcoma is the most common sarcoma of the retroperitoneum. Liposarcomas are typically low grade, and present at an advanced stage and a large size. We report a case of a large retroperitoneal liposarcoma, approximately 50 kg, encasing both kidneys, which was managed via a two-stage resection and staged renal auto-transplantation into the intra-peritoneal pelvis. The patient maintained normal renal function throughout, and remains disease free two years post-resection. Renal auto-transplantation with pelvic placement may facilitate improved margin-free resection. Renal relocation may allow the use of curative-intent ablative therapies such as radiofrequency ablation and radiation in cases of retroperitoneal recurrence.
  • Thumbnail Image
    Item
    Corrigendum to "The Role of Costimulation Blockade in Solid Organ and Islet Xenotransplantation"
    (Hindawi, 2018-03-22) Samy, Kannan P.; Butler, James R.; Li, Ping; Cooper, David K. C.; Ekser, Burcin; Surgery, School of Medicine
  • Thumbnail Image
    Item
    Dendritic Cell Therapy in Transplantation, Phenotype Governs Destination and Function
    (Lippincott, Williams & Wilkins, 2018-10) Samy, Kannan P.; Brennan, Todd V.; Surgery, School of Medicine
  • Thumbnail Image
    Item
    The Role of Costimulation Blockade in Solid Organ and Islet Xenotransplantation
    (Hindawi, 2017) Samy, Kannan P.; Butler, James R.; Li, Ping; Cooper, David K. C.; Ekser, Burcin; Department of Surgery, School of Medicine
    Pig-to-human xenotransplantation offers a potential bridge to the growing disparity between patients with end-stage organ failure and graft availability. Early studies attempting to overcome cross-species barriers demonstrated robust humoral immune responses to discordant xenoantigens. Recent advances have led to highly efficient and targeted genomic editing, drastically altering the playing field towards rapid production of less immunogenic porcine tissues and even the discussion of human xenotransplantation trials. However, as these humoral immune barriers to cross-species transplantation are overcome with advanced transgenics, cellular immunity to these novel xenografts remains an outstanding issue. Therefore, understanding and optimizing immunomodulation will be paramount for successful clinical xenotransplantation. Costimulation blockade agents have been introduced in xenotransplantation research in 2000 with anti-CD154mAb. Most recently, prolonged survival has been achieved in solid organ (kidney xenograft survival > 400 days with anti-CD154mAb, heart xenograft survival > 900 days, and liver xenograft survival 29 days with anti-CD40mAb) and islet xenotransplantation (>600 days with anti-CD154mAb) with the use of these potent experimental agents. As the development of novel genetic modifications and costimulation blocking agents converges, we review their impact thus far on preclinical xenotransplantation and the potential for future application.